Effect of off-label use of oncology drugs on pharmaceutical costs: The rituximab experience

被引：0
|
作者：
Kocs, D
Fendrick, AM
机构：
[1] Univ Michigan, Med Ctr, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Ctr, Div Gen Med, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Publ Hlth, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Sch Med, CHOICES, Ann Arbor, MI 48109 USA
来源：
AMERICAN JOURNAL OF MANAGED CARE | 2003年 / 9卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
GOAL To provide comprehensive and current information concerning the. off-label use of oncology drugs and its effects on pharmaceutical costs. AUDIENCE This activity is designed for pharmacy & therapeutics committee members; group practice directors; physicians specializing in oncology; hospital administrators; and institutional, home-health and/or infusion pharmacists. LEARNING OBJECTIVES Upon completion of this educational activity, the participant should be able to: Interpret the definition and meaning of "off-label" use of a drug. List the pertinent factors that promote, inhibit, or have a mixed influence on off-label use of a drug. Discuss the influence on oncology drug expenditures of off-label use of oncology drugs, with specific emphasis on rituximab costs.
引用
收藏
页码：393 / 400
页数：8
相关论文
共 50 条
  • [21] Off-label use in oncology: an inexhaustible topic?!
    Weissbach, L.
    Riese, J.
    UROLOGE, 2006, 45 (11): : 1410 - +
  • [22] The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)
    Casali, P. G.
    ANNALS OF ONCOLOGY, 2007, 18 (12) : 1923 - 1925
  • [23] Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience
    Salvo, Ida
    Landoni, Giovanni
    Mucchetti, Marta
    Cabrini, Luca
    Pani, Luca
    PEDIATRIC ANESTHESIA, 2014, 24 (06) : 625 - 631
  • [24] Off-label use of targeted therapies in oncology
    Leveque, Dominique
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2016, 7 (02): : 253 - 257
  • [25] OFF-LABEL DRUG USE IN ONCOLOGY PATIENTS
    Moreno, Kathryn
    Parks, Debra
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [26] Off-label use of rituximab in dermatology: pemphigus treatment
    Bomm, Lislaine
    Fracaroli, Taina Scalfoni
    Sodre, Joao Luz
    Bressan, Aline
    Gripp, Alexandre Carlos
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2013, 88 (04) : 676 - 678
  • [27] Extent and patterns of off-label use of rituximab for SLE
    Iñaki Sanz
    Nature Reviews Rheumatology, 2016, 12 : 700 - 702
  • [28] Off-label use of rituximab in a tertiary Queensland hospital
    Butterly, S. J.
    Pillans, P.
    Horn, B.
    Miles, R.
    Sturtevant, J.
    INTERNAL MEDICINE JOURNAL, 2010, 40 (06) : 443 - 452
  • [29] Off-label use of rituximab in patients with multiple sclerosis
    Naegelin, Y.
    Kappos, L.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S123 - S123
  • [30] Off-Label Use of Rituximab in a Multipayer Insurance System
    Van Allen, Eliezer M.
    Miyake, Todd
    Gunn, Nathan
    Behler, Caroline M.
    Kohlwes, Jeff
    JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (02) : 76 - 79
12345